tiprankstipranks
Supernus raises 2024 revenue outlook to $630M-$650M from $600M-$625M
PremiumThe FlySupernus raises 2024 revenue outlook to $630M-$650M from $600M-$625M
3M ago
Supernus jumps 3% to $35.77 after Q3 beat, guidance raise
Premium
The Fly
Supernus jumps 3% to $35.77 after Q3 beat, guidance raise
3M ago
Is SUPN a Buy, Before Earnings?
Premium
Pre-Earnings
Is SUPN a Buy, Before Earnings?
3M ago
Piper downgrades Supernus to Neutral on slower Qelbree growth
PremiumThe FlyPiper downgrades Supernus to Neutral on slower Qelbree growth
5M ago
Supernus downgraded to Neutral from Overweight at Piper Sandler
Premium
The Fly
Supernus downgraded to Neutral from Overweight at Piper Sandler
5M ago
Supernus announces FDA acceptance of SPN-830 apomorphine infusion device NDA
Premium
The Fly
Supernus announces FDA acceptance of SPN-830 apomorphine infusion device NDA
5M ago
Supernus gives interim data on open-label Phase 2a study of SPN-817 in epilepsy
PremiumThe FlySupernus gives interim data on open-label Phase 2a study of SPN-817 in epilepsy
8M ago
Supernus  sees FY24 revenue $580M-$620M, consensus $601.46M
Premium
The Fly
Supernus sees FY24 revenue $580M-$620M, consensus $601.46M
9M ago
Supernus reports Q1 EPS 0c, consensus 38c
Premium
The Fly
Supernus reports Q1 EPS 0c, consensus 38c
9M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100